Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

Bayer912 enrolled

Overview

The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of "naïve" patients

Study Type

OBSERVATIONAL

Enrollment

912

Conditions

Wet Macular Degeneration

Interventions

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)DRUG

Administration by intravitreal injection

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * "Naïve" patients with wet AMD(age-related macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC). Exclusion Criteria: * Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye. * Any concomitant therapy with another agent to treat wet AMD in the study eye. * Any prior or concomitant therapy with another drug for wAMD.

Locations (1)

Unnamed facility

Multiple Locations, Italy

Outcomes

Primary Outcomes

Mean change of visual acuity from baseline to 12 months.

Time frame: Baseline to 12 months

Mean change of visual acuity from baseline to 24 months.

Time frame: Baseline to 24 months